Moving Immunotherapy into Early-Stage Lung Cancer

Anna Linehan, Patrick M. Forde

Research output: Contribution to journalReview articlepeer-review


Blockade of the programmed cell death 1 immune inhibitory pathway has revolutionized the treatment of advanced non-small cell lung cancer and led to significant improvements in overall survival. In contrast, early-stage surgically resectable lung cancer has had few treatment advances in many years and continues to be associated with a high risk of relapse despite apparent curative resection. In this review, we discuss the many ongoing efforts to incorporate programmed cell death 1 pathway blockade into the treatment paradigm for surgically resectable lung cancer both as adjuvant and neoadjuvant therapy. We review the early-phase results from neoadjuvant clinical trials, the landscape of phase III trials that are ongoing, and look to the future of immune checkpoint blockade as a potential curative therapy for surgically resectable lung cancer.

Original languageEnglish (US)
Pages (from-to)543-547
Number of pages5
JournalCancer Journal (United States)
Issue number6
StatePublished - Nov 2020


  • Adjuvant
  • PD-1
  • PD-L1
  • atezolizumab
  • durvalumab
  • early stage
  • immune checkpoint blockade
  • immunotherapy
  • lung cancer
  • neoadjuvant
  • nivolumab
  • pembrolizumab
  • resectable
  • sintilimab
  • surgery

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Moving Immunotherapy into Early-Stage Lung Cancer'. Together they form a unique fingerprint.

Cite this